PMID- 22246523
OWN - NLM
STAT- MEDLINE
DCOM- 20130726
LR  - 20211021
IS  - 1559-131X (Electronic)
IS  - 1357-0560 (Linking)
VI  - 29
IP  - 4
DP  - 2012 Dec
TI  - MicroRNA-34a affects the occurrence of laryngeal squamous cell carcinoma by 
      targeting the antiapoptotic gene survivin.
PG  - 2473-80
LID - 10.1007/s12032-011-0156-x [doi]
AB  - Survivin has been shown to be an ideal target for cancer gene therapy because of 
      its strong antiapoptotic effect. MicroRNA-34a (miR-34a) can function as a tumor 
      suppressor in some cancers through negative regulation of gene expression. 
      However, the relationship between miR-34a and survivin in larynx squamous cell 
      carcinoma (LSCC) has not been explored. The abundance of survivin mRNA and 
      miR-34a in LSCC tissues were measured using quantitative real-time polymerase 
      chain reaction. Their expression levels were analyzed and correlated with tumor 
      differentiation, lymphatic metastasis, clinical stages, and survival rates. 
      MiR-34a mimic was transfected using liposomes to increase its level in LSCC 
      cancer cell line, Hep-2. The effects of miR-34a on survivin protein expression 
      were tested using western blot analysis. Cell cycle analyses were performed using 
      flow cytometry. The results showed that transfection of miR-34a mimic 
      significantly suppressed cell proliferation with decreased survivin protein 
      expression, but did not affect mRNA expression level. The results from LSCC 
      tissue samples showed that miR-34a was downregulated, while survivin expression 
      was upregulated. The miR-34a levels were negatively correlated with histologic 
      differentiation and were positively correlated with survival rate. MiR-34a 
      significantly suppressed cell proliferation by arresting cells at G0/G1 phase in 
      Hep-2 cells. These results indicated that miR-34a may affect the occurrence of 
      LSCC by targeting survivin.
FAU - Shen, Zhisen
AU  - Shen Z
AD  - Department of Otorhinolaryngology (Head and Neck Surgery), Lihuili Hospital of 
      Ningbo University, Ningbo University School of Medicine, Ningbo, 315040, China. 
      szs7216@sina.com
FAU - Zhan, Guowen
AU  - Zhan G
FAU - Ye, Dong
AU  - Ye D
FAU - Ren, Yuan
AU  - Ren Y
FAU - Cheng, Lixin
AU  - Cheng L
FAU - Wu, Zhenhua
AU  - Wu Z
FAU - Guo, Junming
AU  - Guo J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120114
PL  - United States
TA  - Med Oncol
JT  - Medical oncology (Northwood, London, England)
JID - 9435512
RN  - 0 (BIRC5 protein, human)
RN  - 0 (Inhibitor of Apoptosis Proteins)
RN  - 0 (MIRN34 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Survivin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Carcinoma, Squamous Cell/*genetics/mortality/pathology
MH  - Cell Cycle
MH  - Cell Line, Tumor
MH  - Disease-Free Survival
MH  - Humans
MH  - Inhibitor of Apoptosis Proteins/*genetics
MH  - Laryngeal Neoplasms/*genetics/mortality/pathology
MH  - MAP Kinase Signaling System
MH  - MicroRNAs/*physiology
MH  - Middle Aged
MH  - Survivin
EDAT- 2012/01/17 06:00
MHDA- 2013/07/28 06:00
CRDT- 2012/01/17 06:00
PHST- 2011/11/28 00:00 [received]
PHST- 2011/12/30 00:00 [accepted]
PHST- 2012/01/17 06:00 [entrez]
PHST- 2012/01/17 06:00 [pubmed]
PHST- 2013/07/28 06:00 [medline]
AID - 10.1007/s12032-011-0156-x [doi]
PST - ppublish
SO  - Med Oncol. 2012 Dec;29(4):2473-80. doi: 10.1007/s12032-011-0156-x. Epub 2012 Jan 
      14.